Viralytics – oncolytic immunotherapies

Viralytics is a biotech company focusing on the development of oncolytic immunotherapies, using the specific property of certain viruses to preferentially infect and kill cancer cells. Viralytics’ lead product candidate is CAVATAK, a proprietary formulation of the common Coxsackievirus Type A21 (CVA21), evaluated in Phase 1 and 2 clinical trials.

Viralytics – oncolytic immunotherapies


One of the most promising area of cancer research involves the use of oncolytic viruses to preferentially infect and kill cancer cells while also potentially stimulating a systemic immune response aimed at specific tumour cells. Viralytics’ lead product, CAVATAK, is a proprietary formulation of an oncolytic common cold virus that has demonstrated anti-tumour activity, along with a promising safety profile in a Phase 2 clinical trial.  CAVATAK acts by attaching itself to a protein highly expressed on many cancer cells surface (ICAM-1). Using this property, CAVATAK can directly target, infect, multiply within, and destroy a wide range of cancer cells. After cancer cells lysis, thousands of viral progeny can spread and replicate this cycle of destruction. And during this process, tumour cell fragments are released, potentially activating the body’s own immune system by identifying the cancerous tumour cells as foreign. Through these selective mechanisms of action, Viralytics’ therapies are designed to provide greater tolerability and efficacy. CAVATAK is currently being evaluated in Phase 1 and 2 clinical trials, both as an intratumoural and intravenous agent, in melanoma, prostate, lung and bladder cancers.

Viralytics is a publicly-held company headquartered in Sydney (Australia). Paul Hopper, Leonard Post and Peter Turvey compose the Board of Directors. Management Team includes Malcolm McColl, Darren Shafren and Robert Vickery. Scientific advisory board is composed by Jeffrey Weisberg, Kevin Harrington, Keith Flaherty, Hardev Pandha and Evanthia Galanis. The annual market opportunity for cancer immunotherapies is estimated at $35 billion by the year 2023, thus positioning Viralytics in a key position with its Oncolytic Immunotherapy technology already protected by numerous patents worldwide.

More about Viralytics :

Viralytics – CAVATAK – Coxsackievirus Type A21 – CVA21 – ICAM-1 – oncolytic immunotherapies

Viralytics – oncolytic immunotherapy – Coxsackievirus – oncolytic virus – ICAM1 – intratumoural – melanoma – Paul Hopper – Leonard Post – Peter Turvey – Malcolm McColl – Darren Shafren – Robert Vickery – Jeffrey Weisberg – Kevin Harrington – Keith Flaherty – Hardev Pandha – Evanthia Galanis